INNOCARE

InnoCare Pharma staged a morning-session rally, closing up 5.07% at HK$14.51 after opening at HK$13.71, driven by a confluence of strong earnings and multiple clinical milestones. The stock climbed from an intraday low of HK$13.82 to a session high of HK$14.51. Q1 2026 revenue surged 46.78% YoY to HK$599 million, net profit soared 523.45% YoY to HK$120 million, net margin reached 20.02%, and EPS of HK$0.068 jumped 535.16% YoY, confirming a profitability inflection. Recent catalysts include soficitinib meeting primary endpoints in Phase II vitiligo and Phase III atopic dermatitis trials, orelabrutinib Phase III CLL/SLL results published in STTT (IF 81.2), first patient dosed for CDH17-targeted ADC ICP-B208, and NDA acceptance for orelabrutinib in ITP. The stock remains 29.63% below its 52-week high of HK$20.62 but has gained 16.08% YTD, trading above both MA20 (HK$12.89) and MA60 (HK$12.45), though the PB of 3.08x and PE of 30.99x suggest valuation already reflects some optimism.

Infracorp climbed in the morning session but then fell back, hitting an intraday high of HKD 14.760 shortly after the open before sliding to HKD 13.950, and finally closing at HKD 13.970, down 4.9% from the previous close of HKD 14.690, with a volume of approximately 3.342 million shares. Despite the company's focus on oncology and autoimmune diseases, the current price is 32.25% below the 52-week high of HKD 20.62, yet it has risen 11.76% YTD and remains above the MA20 (HKD 12.716) and MA60 (HKD 12.455), suggesting a still-bullish medium-term trend. However, the 5.5% drop from the intraday high in the morning session, coupled with higher turnover, indicates short-term profit-taking pressure.

InnoCare Pharma opened higher in the morning session and climbed steadily from HK$14.35 to HK$15.05, up approximately 4.9%, driven primarily by recent positive clinical data and regulatory progress for its core drug Orelabrutinib. The company published Phase 3 results in STTT (IF=81.2) showing Orelabrutinib significantly prolonged progression-free survival in treatment-naïve CLL/SLL; a Phase 3 trial for SLE has dosed its first patient in China, and an NDA for primary immune thrombocytopenia was accepted by Chinese regulators. Financially, Q1 2026 revenue rose 47% YoY to HK$599 million, net profit surged 523% YoY to HK$120 million, with a net margin of 20%. The current price of HK$15.06 is 27% below the 52-week high of HK$20.62, up 20.5% YTD, and has surpassed both the 20-day MA (HK$12.35) and 60-day MA (HK$12.50). However, the intraday low of HK$14.35 suggests some near-term profit-taking pressure remains.

InnoCare Pharma opened lower and rallied sharply in the morning session, driven by strong Q1 earnings and clinical progress. The stock rose 5.0% to HK$14.07. Q1 revenue surged 46.78% YoY to ~HK$599 million, net profit jumped 523.45% YoY to ~HK$120 million, with a net profit margin of 20.02%. The company also announced first patient dosed for its novel CDH17-targeted ADC ICP-B208 in China and first patient enrollment in the Phase III trial of orelabrutinib for SLE. At HK$14.08, the stock remains 31.72% below its 52-week high of HK$20.62 but has recovered above both the 20-day (HK$11.795) and 60-day (HK$12.545) moving averages, up 12.64% YTD. However, the stock previously hit a 52-week low of HK$9.65 earlier this year, suggesting the recent rally may face near-term pullback risks.

InnoCare Pharma opened lower in the morning session at HKD 13.040, then staged a sharp rebound, hitting an intraday high of HKD 14.070 and gaining 5.08% with a turnover of HKD 36.77 million. The rally was primarily driven by a series of positive catalysts: Q1 2026 revenue surged 46.78% YoY to HKD 599.3 million, while net profit soared 523.45% YoY to HKD 120.0 million, confirming a clear inflection point in profitability. Additionally, positive Phase 2b data for orelabrutinib in systemic lupus erythematosus presented at the 2026 EULAR congress, a Phase 3 trial initiation, and the clinical trial approval/first patient dosing for the novel CDH17-targeted ADC ICP-B208 all reinforced pipeline momentum. However, the current price of HKD 14.07 remains approximately 31.77% below its 52-week high of HKD 20.62, despite a year-to-date gain of 12.56%, and the stock's relatively high PE of 30.02x and PB of 2.98x may temper further upside.